Tempus AI, the US-based healthcare technology company, has announced a definitive agreement to acquire Personalis, a genomic testing firm, for roughly $1.5 billion in stock. The deal, announced on 20 July 2026, sees Personalis shareholders receive 0.75 Tempus shares for each Personalis share held, valuing the target at $1.50 per share — a significant premium over its recent trading levels.
The transaction underscores the accelerating consolidation in precision oncology, where artificial intelligence is increasingly used to analyse genetic data and tailor cancer treatments. Tempus, founded by Eric Lefkofsky, has built a vast library of clinical and molecular data, while Personalis specialises in ultra-sensitive tumour sequencing. The combined entity is expected to offer a more comprehensive platform for drug developers and healthcare providers.
For UK investors, the deal highlights the growing appetite for AI-driven healthcare plays. While both companies are US-headquartered, their technologies are used by NHS Genomics Medicine Service and UK biotech firms. The acquisition could accelerate the adoption of AI-based diagnostics in Britain, potentially improving cancer care pathways and reducing costs for the health service.
Analysts at Peel Hunt noted that the deal reflects a broader trend of AI firms acquiring specialised genomics companies to secure proprietary data sets. “This is a bet on data moats,” said one analyst. “Tempus is paying up for Personalis’s unique long-read sequencing capabilities, which are hard to replicate.” The transaction is subject to regulatory approvals and Personalis shareholder votes, with completion expected later this year.
The FTSE 100 edged down 0.2% on the day to 8,215.6, as broader healthcare stocks saw mixed trading. Shares in UK-listed genomics firms such as Oxford Nanopore Technologies rose 1.8% on the news, reflecting investor optimism about sector M&A. Tempus shares, which trade on the Nasdaq, were up 3.4% in pre-market trading.